Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling

Although progesterone (P4) has been implicated to offer protection against ovarian cancer (OCa), little is known of its mechanism of action. The goal of this study was to identify P4-regulated genes that have anti-OCa action. Three immortalized nontumorigenic human ovarian surface epithelial (HOSE) cell lines and three OCa (OVCA) cell lines were subjected to 5 days of P4 treatment. Transcriptional profiling with a cDNA microarray containing ≈2400 known genes was used to identify genes (1) whose expression was consistently downregulated in OVCA cell lines compared to HOSE cell lines, and (2) whose expression was restored in OCa cell lines by P4 treatment. From the candidates selected, activating transcription factor-3 (ATF-3), caveolin-1, deleted in liver cancer-1 (DLC-1), and nonmetastatic clone 23 (NM23-H2) were chosen for post hoc functional studies based on their previously reported action as tumor suppressors or apoptosis inducers. Semiquantitative RT–PCR analyses confirmed loss of or reduced transcription of these genes in OVCA cells when compared to HOSE cells and their upregulation following P4 treatment. Hormonal specificity was demonstrated by blockade experiments with a progestin antagonist RU 38486. Ectopic expression of caveolin-1, DLC-1, and NM23-H2 caused growth inhibition in OVCA cell cultures, but not in HOSE cell cultures, while forced expression of ATF-3 suppressed growth in both. Overexpression of AFT-3 also enhanced caspase-3 activity in both HOSE and OVCA cells, whereas ectopic expression of caveolin-1 and DLC-1 only activated this enzyme in OCa cells. In contrast, NM23-H2 overexpression was ineffective in activating caspase-3. Overexpression of any of the four genes in OCa cells reduced soft-agar colony formation and cell invasiveness. Taken together, we have identified four new P4-regulated, antitumor genes for OCa. However, their modes of action differ significantly; ATF-3 primarily functions as an apoptosis inducer, NM23-H2 as a suppressor of cell motility, and caveolin-1 and DLC-1 exhibiting features of classical tumor suppressors. To the best of our knowledge, except for NM23-H2, this is the first report linking P4 to the regulation of these tumor suppressor/proapoptotic genes, which could serve as future therapeutic targets.

[1]  D. Eccles,et al.  Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours. , 1995, British Journal of Cancer.

[2]  S. Seitz,et al.  Analysis of DLC-1 expression in human breast cancer , 2003, Journal of Cancer Research and Clinical Oncology.

[3]  P. Giangrande,et al.  Mapping and Characterization of the Functional Domains Responsible for the Differential Activity of the A and B Isoforms of the Human Progesterone Receptor* , 1997, The Journal of Biological Chemistry.

[4]  Maureen E. Callow,et al.  Use of Self-Assembled Monolayers of Different Wettabilities To Study Surface Selection and Primary Adhesion Processes of Green Algal (Enteromorpha) Zoospores , 2000, Applied and Environmental Microbiology.

[5]  Shuk-Mei Ho,et al.  Estrogen, Progesterone and Epithelial Ovarian Cancer , 2003, Reproductive biology and endocrinology : RB&E.

[6]  S. Nishizuka,et al.  Commonly deleted region on the long arm of chromosome 7 in differentiated adenocarcinoma of the stomach. , 1997, British Journal of Cancer.

[7]  I. Fentiman,et al.  Pregnancy and menstrual hormone levels in mothers of twins compared to mothers of singletons. , 1998, Annals of human biology.

[8]  J. Berek,et al.  Ovarian cancer: epidemiology, biology, and prognostic factors. , 2000, Seminars in surgical oncology.

[9]  S. Dudoit,et al.  Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. , 2002, Nucleic acids research.

[10]  R. Knapp,et al.  Factors affecting the association of oral contraceptives and ovarian cancer. , 1982, The New England journal of medicine.

[11]  J. Couet,et al.  Reduction of caveolin 1 gene expression in lung carcinoma cell lines. , 1999, Biochemical and biophysical research communications.

[12]  David I. Smith,et al.  Loss of heterozygosity on the long arm of human chromosome 7 in sporadic renal cell carcinomas , 1997, Oncogene.

[13]  R. Sokol,et al.  Maternal-Fetal Medicine: Principles and Practice , 1985 .

[14]  S. Thorgeirsson,et al.  DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity , 2003, Oncogene.

[15]  R. Berkowitz,et al.  Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). , 1995, Experimental cell research.

[16]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[17]  H. Billig,et al.  Expression of Progesterone Receptor (PR) A and B Isoforms in Mouse Granulosa Cells: Stage-Dependent PR-Mediated Regulation of Apoptosis and Cell Proliferation1 , 2003, Biology of reproduction.

[18]  J. Schildkraut,et al.  Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. , 2002, Journal of the National Cancer Institute.

[19]  T. Tsuruo,et al.  Involvement of transcriptional repressor ATF3 in acceleration of caspase protease activation during DNA damaging agent‐induced apoptosis , 2001, Journal of cellular physiology.

[20]  Ericka Stricklin-Parker,et al.  Ann , 2005 .

[21]  P. Athanassiadou,et al.  Expression of p53, bcl-2 and heat shock protein (hsp72) in malignant and benign ovarian tumours , 1998, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[22]  W. Welshons,et al.  Transcription factor accessibility and histone acetylation of the progesterone receptor gene differs between parental MCF-7 cells and a subline that has lost progesterone receptor expression. , 2004, Gene.

[23]  S. Mok,et al.  Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells , 2003, Oncogene.

[24]  Tsonwin Hai,et al.  Transcriptional Autorepression of the Stress-inducible GeneATF3 * , 2000, The Journal of Biological Chemistry.

[25]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[26]  P. Thomas,et al.  Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Chen,et al.  ATF3 Gene , 1996, The Journal of Biological Chemistry.

[28]  Q. Gao,et al.  Progesterone induces apoptosis and up‐regulation of p53 expression in human ovarian carcinoma cell lines , 1997, Cancer.

[29]  Shuk-Mei Ho,et al.  Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells , 1999 .

[30]  Jung Weon Lee,et al.  Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells , 2003, Oncogene.

[31]  J. Yokota,et al.  Ovarian Cancer: Loss of Heterozygosity Frequently Occurs in the ATM Gene, but Structural Alterations Do Not Occur in This Gene , 1999, Oncology.

[32]  S. Ho,et al.  Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL , 2003, Oncogene.

[33]  S. Mok,et al.  Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. , 2002, Journal of the National Cancer Institute.

[34]  Progress in Clinical and Biological Research , 1989 .

[35]  S. Yu,et al.  Apoptosis induced by progesterone in human ovarian cancer cell line SNU‐840 , 2001, Journal of cellular biochemistry.

[36]  M. Maresh,et al.  Maternal Fetal Medicine. Principles and Practice , 1989 .

[37]  H. Adami,et al.  Parity, age at first childbirth, and risk of ovarian cancer , 1994, The Lancet.

[38]  C. Albigès-Rizo,et al.  New Insights into Nm23 Control of Cell Adhesion and Migration , 2003, Journal of bioenergetics and biomembranes.

[39]  Andrew G. Glen,et al.  APPL , 2001 .

[40]  J. Smyth,et al.  Progress in Clinical and Biological Research , 1979 .

[41]  M. Fukumoto,et al.  Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: correlation with tumour progression and nm23 gene expression. , 1995, British Journal of Cancer.

[42]  Tsonwin Hai,et al.  The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. , 2001, Gene.